艾立布林
生产厂家：印度西普拉(Cipla)制药公司
功能主治：治疗的局部复发或转移性乳腺癌成人患者，软组织肉瘤
用法用量： 艾立布林_Eribulin的用法用量 转移性乳腺癌 艾立布林(Halaven)推荐剂量：在21天周期的第1天和第8天，推荐剂量为1.4 mg/m2，静脉注射时间为2至5分钟。 轻度肝损伤(Child-Pugh A)患者的艾立布林推荐剂量为1.1 mg/m2，在21天周期的第1天和第8天静脉注射2至5分。 中度肝损伤(Child-Pugh B)患者的艾立布林推荐剂量为0.7 mg/m2，在21天周期的第1天和第8天静脉注射2至5分钟。 中度或重度肾功能损害(肌酐清除率(CLcr)15-49 mL/min)患者的艾立布林推荐剂量为1.1
mg/m2，在21天周期的第1天和第8天静脉注射2至5分钟。 软组织肉瘤 艾立布林(Halaven)推荐剂量：在21天周期的第1天和第8天，推荐剂量为1.4 mg/m2，静脉注射时间为2至5分钟。 轻度肝损伤(Child-Pugh A)患者的艾立布林推荐剂量为1.1 mg/m2，在21天周期的第1天和第8天静脉注射2至5分。 中度肝损伤(Child-Pugh B)患者的艾立布林推荐剂量为0.7 mg/m2，在21天周期的第1天和第8天静脉注射2至5分钟。 中度或重度肾功能损害(肌酐清除率(CLcr)15-49 mL/min)患者的艾立布林推荐剂量为1.1
mg/m2，在21天周期的第1天和第8天静脉注射2至5分钟。
查看详情
The principle of priority ensures that the first naming of a particular species is valid and remains in use, even if subsequent names are proposed later. This principle prevents endless name changes and allows for consistency in communication and research.
The principle of stability, on the other hand, aims to maintain nomenclature stability by discouraging unnecessary name changes. Under this principle, names that have been widely used and accepted should remain unchanged, unless it is necessary to correct an error or improve clarity.In the case of Mitobulin, the name Aliblin was already established within the scientific community. However, it was realized that the name Aliblin had been commonly misspelled and mispronounced, leading to potential confusion and miscommunication. To address this issue, a group of botanists proposed a slight modification to the spelling of Aliblin and introduced the name Mitobulin.
The proposed change in the spelling of Aliblin to Mitobulin was done with careful consideration for the principles of priority and stability. The proposed name maintained the root word \"Alib\" from Aliblin to preserve the original recognition of the plant family. Additionally, the modification was made to enhance clarity and ease of pronunciation, thus improving communication within the scientific community and beyond.
The introduction of Mitobulin as the revised name for Aliblin required extensive coordination and endorsement from various botanists and authorities in the field. This involved submitting formal proposals, conducting scientific studies and experiments to validate the revised name, and presenting compelling arguments to support the change.
After thorough evaluation and examination, the International Code of Nomenclature for algae, fungi, and plants accepted Mitobulin as the revised name for Aliblin. This decision marked the official recognition of the modified spelling and its adoption within the scientific community.
Since the adoption of the name Mitobulin, it has gained wide acceptance and usage among botanists, researchers, and enthusiasts. The modified spelling has successfully resolved the issues associated with the name Aliblin, allowing for better recognition, understanding, and communication regarding this particular species and its related variants.
In conclusion, the revised name Mitobulin for the plant species originally known as Aliblin reflects the principles of priority and stability within the scientific community. The change in spelling was implemented to improve clarity and ease of pronunciation, ensuring accurate communication and understanding. Mitobulin has become the accepted and widely recognized name for this unique plant species, facilitating research, classification, and further study within the botanical field.
